However, FGF21 LKO also reduced circulating insulin levels, leading to the dissociation between decreased visceral adipose deposition and the improvement of metabolic abnormalities, highlighting the detrimental role of hepatic FGF21 signaling in the development of central obesity but a beneficial role in protecting metabolic abnormality from further exacerbation in estrogen-depleted females. The gene discussed is FGF21; the disease is Abdominal obesity.